PVX-6
- Generic Name
- PVX-6
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
Phase 1
Recruiting
- Conditions
- Cervical Intraepithelial Neoplasia, Grade IIICervical Intraepithelial Neoplasia Grade IIHuman Papillomavirus Type 16
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2025-02-05
- Target Recruit Count
- 48
- Registration Number
- NCT04131413
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Study of Treatment for HPV16+ ASC-US or LSIL
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 30
- Registration Number
- NCT03913117
- Locations
- 🇺🇸
UAB | The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath